Skip to main navigation Skip to search Skip to main content

Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases

  • Bryndis Yngvadottir
  • , Avgi Andreou
  • , Laia Bassaganyas
  • , Alexey Larionov
  • , Alex J. Cornish
  • , Daniel Chubb
  • , Charlie N. Saunders
  • , Philip S. Smith
  • , Huairen Zhang
  • , Yasemin Cole
  • , James Larkin
  • , Lisa Browning
  • , Samra Turajlic
  • , Kevin Litchfield
  • , Richard S. Houlston
  • , Eamonn R. Maher
    • University of Cambridge
    • The Beatson Institute for Cancer Research, Glasgow
    • Department of Medical Oncology, Hospital Universitario Dr Peset, Valencia, Spain.
    • Department of Experimental Psychology, Anna Watts Building, University of Oxford, Oxford; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Department of Psychiatry, Warneford Hospital, Warneford Ln, Headington, Oxford
    • University College London

    Research output: Contribution to journalArticlepeer-review

    12 Downloads (Pure)

    Abstract

    Renal cell carcinoma (RCC) occurs in a number of cancer predisposition syndromes, but the genetic architecture of susceptibility to RCC is not well defined. We investigated the frequency of pathogenic and likely pathogenic (P/LP) germline variants in cancer susceptibility genes (CSGs) within a large series of unselected RCC participants. Whole-genome sequencing data on 1336 RCC participants and 5834 controls recruited to the UK 100 000 Genomes Project, a nationwide multicentre study, was analyzed to identify rare P/LP short variants (single nucleotide variants and insertions/deletions ranging from 1 to 50 base pairs) and structural variants in 121 CSGs. Among 1336 RCC participants [mean: 61.3 years (±12 SD), range: 13-88 years; 64% male], 85 participants [6.4%; 95% CI (5.1, 7.8)] had one or more P/LP germline variant in a wider range of CSGs than previously recognized. A further 64 intragenic variants in CSGs previously associated with RCC were classified as a variant of uncertain significance (VUS) (24 'hot VUSs') and were considered to be of potential clinical relevance as further evaluation might results in their reclassification. Most patients with P variants in well-established CSGs known to predispose to renal cell carcinoma (RCC-CSGs) were aged <50 years. Burden test analysis for filtered variants in CSGs demonstrated a significant excess of CHEK2 variants in European RCC participants compared with the healthy European controls (P = 0.0019). Approximately, 6% of the patients with RCC unselected for family history have a germline variant requiring additional follow-up analysis. To improve diagnostic yield, we suggest expanding the panel of RCC-CSGs tested to include CHEK2 and all SDHx subunits and raising the eligibility criteria for age-based testing.

    Original languageEnglish
    Pages (from-to)3001-3011
    Number of pages11
    JournalHuman Molecular Genetics
    Volume31
    Issue number17
    Early online date20 Apr 2022
    DOIs
    Publication statusPublished - 1 Sept 2022

    Bibliographical note

    Copyright © The Author(s) 2022. Published by Oxford University Press.
    This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

    Funding

    This work was supported by the European Research Council (Advanced Researcher Award to E.R.M.), National Institute for Health and Care research (NIHR) [Senior Investigator Award to E.R.M. and Cambridge NIHR Biomedical Research Centre (BRC-1215-20014) to E.R.M.] and Cancer Research UK Cambridge Cancer Centre (grant reference number SSAG/085 for A.A. and E.R.M.) and VHL UK/Ireland. The University of Cambridge has received salary support in respect of E.R.M. from the National Health Service (NHS) in the East of England through the Clinical Academic Reserve. R.S.H. acknowledges grant support from Cancer Research UK (C1298/A8362), the Wellcome Trust (214388) and the Medical Research Council. L.B. is part funded by the NIHR Oxford Biomedical Research Centre (Molecular Diagnostics Theme). K.L. is funded by the UK Medical Research Council (MR/V033077/1), Rosetrees Trust (A2437) and Cancer Research UK (C69256/A30194). S.T. is funded by Cancer Research UK (grant reference number A29911); the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC10988), the UK Medical Research Council (FC10988) and the Wellcome Trust (FC10988); the NIHR BRC at the Royal Marsden Hospital and Institute of Cancer Research (grant reference number A109); the Royal Marsden Cancer Charity; The Rosetrees Trust (grant reference number A2204); Ventana Medical Systems Inc (grant reference numbers 10467 and 10530); the National Institute of Health (U01 CA247439) and Melanoma Research Alliance (Award Ref no 686061).

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • cancer
    • renal cell carcinoma
    • genes
    • genome
    • diagnosis
    • neoplasms
    • chek2 gene
    • whole genome sequencing

    Fingerprint

    Dive into the research topics of 'Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases'. Together they form a unique fingerprint.

    Cite this